Novel therapies have potential to improve outcomes in patients with acute myeloid leukemia (AML) harboring FLT3-ITD mutations that have high risk of relapse and poor survival following standard of care (SOC) cytarabine/anthracycline-based induction/consolidation chemotherapy.
tion); 1 at DL-1 (pericarditis). Maximum tolerated dose (MTD) was identified as DL-1. Most common grade 3/4 adverse events were febrile neutropenia (47%), neutropenia (42%), thrombocytopenia (32%), and anemia (26%). There were no apparent additional toxicities with addition of quizartinib to chemotherapy although grade 1 QT prolongation was observed at MTD. Sixteen patients (84%) achieved a response; 14 (74%) composite complete response; 2 (11%) morphologic leukemia-free state. The phase 3 QuANTUM-First trial (NCT02668653) is further evaluating the effect of quizartinib plus SOC chemotherapy in ndAML FLT3-ITD mutated patients.
| I N TR ODU C TI ON
One of the most common molecular alterations observed in patients with ndAML is internal tandem duplication (ITD) mutation of the FLT3 receptor, a driver mutation for disease progression that occurs in approximately 25% of cases. [1] [2] [3] [4] [5] [6] FLT3-ITD mutation identifies a high-risk population of AML patients with an increased risk of early relapse, increased mortality following SOC chemotherapy, and a high need for improved treatment options. 2, [7] [8] [9] Point mutations within the tyrosine kinase domain of FLT3 have been reported in approximately 7% of patients with AML but they have not been definitively linked to patient prognosis. 9, 10 Early clinical studies evaluating FLT3 inhibitors such as sunitinib and lestaurtinib in patients with AML demonstrated positive results. [11] [12] [13] [14] However, these agents were limited by poor target selectivity, suboptimal pharmacokinetic (PK)/pharmacodynamic (PD) properties, and off-target effects. In phase 2 trials, treatment with the multikinase inhibitor midostaurin demonstrated transient single-agent antileukemic activity in patients with ndAML or R/R AML. 15, 16 In more recent phase 1/2 studies, midostaurin in combination with chemotherapy induced hematologic responses in patients with ndAML or R/R AML, albeit with increased rates of hematologic and other toxicities. [17] [18] [19] [20] The phase 3 RATIFY study (NCT00651261) demonstrated significant overall survival benefit for midostaurin in combination with standard induction and consolidation chemotherapy in patients with FLT3-mutated ndAML. 21 Based on results of RATIFY, midostaurin was approved in combination with chemotherapy for treatment of adult patients with ndAML characterized by a FLT3
mutation.
An important limitation of first generation, less potent, FLT3 inhibitors is that while they are able to clear blasts from peripheral blood when used at their MTD, they often have little effect on bone marrow blasts. 22 Quizartinib is the first member of a next-generation class of FLT3 inhibitors that demonstrates more potent binding to FLT3, more selective inhibition of FLT3 kinase activity, and more potent growth inhibitory activity in AML cells harboring FLT3-ITD mutation vs multikinase inhibitors including midostaurin and lestaurtinib. [23] [24] [25] Importantly, quizartinib has demonstrated very high single agent activity in patients with FLT3-ITD mutated AML, with reported composite complete remission rates between 46% and 57%, overall response rates between 65% and 78%, and high rates (35%-42%) of successful bridging to allogeneic hematopoietic stem cell transplantation (allo-HSCT). [26] [27] [28] [29] [30] [31] Here, we report results of the first phase 1 study to evaluate safety and tolerability of quizartinib in combination with standard cytarabine/daunorubicin induction and high-dose cytarabine (HiDAC) consolidation chemotherapy in patients with ndAML. The study was focused on safety and tolerability of quizartinib in combination with chemotherapy, and patients enrolled in the study were unselected for FLT3 mutation status. However, baseline assessment of FLT3 permitted analysis of responses by mutational status. 
| M E TH ODS

| Study design
| Part 1: Quizartinib dose escalation
Quizartinib dose escalation was planned in successive cohorts of 5 or 6 patients (with minimum of 3 females in each cohort) to determine MTD in combination with cytarabine/daunorubicin-based chemotherapy.
A modified 3 1 3 design was used, allowing for concurrent enrollment of 2 to 6 patients into a cohort based on number of evaluable patients enrolled, number experiencing DLTs, and number at risk for developing a DLT. Intrapatient dose escalations were not permitted.
Quizartinib dihydrochloride (hereafter referred to as quizartinib) was administered as an oral solution at least 1 hour before or 2 hours after a meal. The first dose level tested (DL1) was quizartinib 60 mg/d (equivalent to 53 mg quizartinib free base) administered on days 4 through 10 of induction therapy. The next dose tested was DL2, DLTs were defined as occurrence of any of the following events during the observation period and considered to be at least possibly related to study drug: a) any grade 3 nonhematologic toxicity occurring after first dose of quizartinib and by day 42 of last induction treatment cycle or before start of the first consolidation cycle, whichever was sooner, b) hematologic toxicities occurring after first dose of quizartinib that did not resolve by day 42 of last induction treatment cycle or before start of the first consolidation cycle, whichever was sooner, including peripheral absolute neutrophil count (ANC) <500/mm 3 (grade 4), non-transfusion-related platelet count <20,000/mm 3 due to documented bone marrow aplasia/hypoplasia (overall marrow cellularity <20%), platelet count <50,000/mm 3 (grade 3) associated with bleeding, or platelet count <25,000/mm 3 (grade 4) requiring blood transfusion, or c) any other study drug-related toxicity that occurred after first dose of quizartinib and caused cessation of study drug during remission induction or during maintenance. MTD was defined as highest dose of quizartinib associated with occurrence of a DLT in <33% of patients in a cohort. MTD was estimated to be dose level at which 1 of 6 or 0 of 5 patients experienced a DLT and one dose level below lowest dose level at which 2 out of 2 to 6 patients experienced a DLT.
| Part 2: MTD evaluation
The planned second part of the study consisted of evaluation of safety, efficacy, and PK of quizartinib administered at MTD determined in part 1 of the study in combination with induction remission or consolidation chemotherapy in expanded cohort of patients. MTD was defined as highest dose associated with occurrence of DLTs at the rate at which lower bound of 95% CI was <25% using the adjusted Wald method. An additional part of the study designed to be conducted in parallel to parts 1 and 2 consisted of evaluation of MTD for quizartinib when administered continuously in 28-day cycles for up to 12 cycles as maintenance therapy in patients who achieved composite complete remission (CRc) following induction or 1 cycle of consolidation chemotherapy. Quizartinib was to be dose-escalated in successive cohorts of 5 or 6 patients to determine maintenance MTD. The first dose level planned was quizartinib 60 mg, administered daily, and dose-escalation decisions were to be made based on DLTs that occurred during first 2 cycles (8 weeks) of maintenance therapy. Once maintenance MTD was determined, all remaining patients coming out of parts 1 and 2 of the study were to be treated at this dose.
However, the study was terminated before the start of part 2 and prior to evaluation of maintenance MTD due to end of the collaboration agreement between the trial sponsors Ambit Biosciences and Astellas Pharma Inc., and total study enrollment consisted of 19 patients in part 1.
| Eligibility
Patients aged between 18 and 60 years with previously untreated ndAML as defined by the World Health Organization (WHO) criteria, 32 documented within 28 days prior to enrollment, and Eastern Coopera- Standard FLT3 testing was conducted locally by investigators. FLT3 mutational status was confirmed for 12 patients by Navigate BioPharma (Carlsbad, CA) using PCR analysis. Results were not collected centrally and enrolled patients were unselected for FLT3 mutation status. 34, 35 CRc rate was the primary efficacy variable. Assessment of minimal residual disease was not required.
| Tolerability and safety assessments
| Exploratory efficacy assessments
| PK assessments
PK analyses were performed for patients with at least 1 measurable study drug concentration and exact date and time of blood sample ALTMAN ET AL.
AJH AJH
| 215 collection and study drug dosing. PK parameters included area under the curve (AUC), maximum concentration (C max ), trough concentration (C trough ), and time to peak concentration (T max ). Efficacy data analyses were conducted on all patients who received at least 1 dose of any study drug and had at least 1 postbaseline efficacy measurement. Response was assessed at each visit, and best overall response was assigned at end of study by the investigator.
| Statistical analyses
Response rate was estimated as number of responders divided by number of patients in the analysis population. Patients with unknown, missing, or no information on response at end of study were treated as nonresponders. Number and percent of patients were summarized by category. 95% CIs were produced for best overall response rate based on Fisher's exact method.
Plasma concentrations and PK parameters were summarized by cohort using descriptive statistics, including number of patients, mean, standard deviation, minimum, median, maximum, geometric mean, and coefficient of variation (CV) of the mean and geometric mean. PK data for quizartinib and AC886 were summarized for cohorts with sufficient data available on day 4 or 10.
| R E SU LTS
| Patient demographics
A total of 19 patients were enrolled between November 2011 and July
A CONSORT diagram is included as Supporting Information Fig-
ure S1. Six patients were treated with quizartinib DL1, 7 with DL2, and 6 with DL-1. Eighteen patients received treatment with quizartinib.
One patient assigned to DL2 had a serious AE (SAE; cerebrovascular accident) on day 1 and was discontinued from study on day 3 before receiving any quizartinib. Patient baseline characteristics were generally similar between the dose levels ( Table 1) . Median age was 43 years.
Sixteen patients (84%) had ECOG performance status of 0 or 1. Nine patients (47%) were positive for FLT3-ITD mutation, defined as FLT3-ITD/WT FLT3 allelic ratio 10% (3 at DL1, 4 at DL2, and 2 at DL-1).
| Treatment exposure and patient disposition
Ten patients (53%) completed treatment, defined as having completed consolidation therapy, having responded to treatment and proceeded to HSCT, or having continued to maintenance therapy (Supporting 
| Safety
| Exploratory efficacy
Overall, 16 patients (84%) achieved a response to therapy (Table 4 ). 
| Pharmacokinetics
The analyses of PK was limited by the small number of patients enrolled and the limited availability of PK samples. Results of the PK analyses are presented in the Supporting Information content. At the preferred term level, patients reporting more than 1 AE were counted only once using the highest severity. c One grade 5 treatment-emergent AE was reported at DL2 (cardiac arrest). The AE was not considered to be related to study drug.
| D I SCUSSION
Quizartinib is a novel FLT3 inhibitor with greater selectivity and potency compared to other broad-acting multikinase inhibitors, 23, 24, [36] [37] [38] and has demonstrated robust single-agent activity in clinical studies in heavily pretreated patients with R/R AML. 26, 28, [39] [40] [41] The importance of FLT3-ITD mutation as a negative prognostic factor in patients with AML has led to the hypothesis that A key finding of the study was early evidence of antileukemic activity of quizartinib in combination with standard chemotherapy.
Responses were observed in 84% of patients, with a notable CRc rate of 74%, and full hematologic/platelet recovery in 75% of responders.
Two-thirds of patients treated at MTD had a CRc. Additionally, no relapses were observed over the course of the study. Forty-seven percent of patients enrolled on trial underwent HSCT. One patient who completed induction and consolidation therapy with the combination regimen proceeded to receive maintenance therapy with single-agent 
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An important limitation of this study is the small size of the patient population. Total study enrollment was limited to 19 patients because of early study termination. This resulted in more limited readouts on safety, PK, and preliminary efficacy. However, the study provided strong evidence that quizartinib can be safely administered in combination with SOC induction/consolidation chemotherapy. Additionally, we observed early evidence of activity and potential to elicit strong responses with this combination regimen. This work supports further clinical evaluation of this regimen in patients with ndAML.
The phase 3 RATIFY study demonstrated significantly improved OS in FLT3 mutated ndAML with standard induction/consolidation chemotherapy plus midostaurin vs placebo. 21 However, it is unclear if the benefit of midostaurin in these patients is related to inhibition of FLT3 activity or other actions of the drug. Given that FLT3-ITD is a driver mutation in AML, 4 ORCID Jessica K. Altman http://orcid.org/0000-0003-1987-1896
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